Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
215 Leser
Artikel bewerten:
(1)

Revolutionizing Regtech: LighthouseAI Secures Strategic Investment and Landmark Law Firm Partnership

LighthouseAI Set to Impact the Regulatory Technology Industry with AI-driven Compliance

LOS ANGELES, CA / ACCESSWIRE / November 16, 2023 / LighthouseAI, an industry leader in compliance solutions for the pharmaceutical supply chain with over 8 years of experience and over 700 clients engaged, today announced their first partnership under their Certified Law Firm Partner Program which enables law firms to incorporate LighthouseAI in their traditional workflows. The successful partnership signing underscores the recent investment from The Legal Tech Fund which will accelerate the development of its AI technology, as well as expand its reach to assist law firms to reduce the time and costs associated with their pharmaceutical clients' supply chain compliance actions.

LighthouseAI's new Certified Law Firm Partner Program enables law firms to leverage LighthouseAI Intelligence to increase practice profitability by reducing the time and cost associated with manual regulatory research and change assessments while maintaining rates. The program provides law firms access to LighthouseAI's AI-powered platform to deliver more efficient and cost-effective counsel to pharmaceutical supply chain clients. As a part of this announcement, LighthouseAI welcomes its first Certified Law Firm Program Partner, Boesen & Snow, a law firm recognized as a national leader in the health industry.

Allyson Snow, Partner and Co-founder of Boeson & Snow, commented: "Boesen & Snow is a firm that prides itself on assembling a team of counsel and professionals who have decades of hands-on healthcare operations experience. We are pleased to be the first Certified Law Firm Program Partner to LighthouseAI and look forward to complimenting their AI-driven solutions."

Sumeet Singh, CEO of LighthouseAI, said, "Assessments on compliance requirements for pharma supply chain and pharmacies has historically been a manual process, with lawyers and experts simply brute forcing their way through 50+ jurisdictions. To solve this challenge, we developed LighthouseAI Intelligence to bridge the practical applicability gap between regulatory content and regulatory knowledge. Law firms can layer their legal services atop our proprietary technology, which will remove the need to perform such laborious tasks and ultimately allow them to focus on high-value work, reduce the cost to their clients, and increase speed for the completion of a project."

This strategic investment from The Legal Tech Fund will enable LighthouseAI to continue enhancing its technology and datasets, expanding into new use cases, and forming partnerships with law firms seeking to leverage AI to improve efficiency, reduce costs, and deliver higher-value services.

Zach Posner, Managing Partner at The Legal Tech Fund, said: "We are excited by the work of Lighthouse AI and the innovation they are bringing to the pharmaceutical compliance space. Our investment aligns with our vision to support transformative solutions that not only reduce regulatory burdens but also empower law firms to deliver unparalleled value to their clients in navigating complex compliance landscapes."

***

About LighthouseAI

LighthouseAI specializes in AI-driven solutions to navigate the complex landscape of regulatory compliance in the life sciences supply chain. With over 8 years of experience, 700 clients, and recognition as thought-leaders, LighthouseAI delivers a SaaS solution that ensures seamless alignment with life sciences compliance regulations, protecting revenue and reducing costs and risks. By eliminating human error and delivering quick, efficient compliance solutions, LighthouseAI revolutionizes the traditional methods of adherence to life sciences regulations. Learn more about how LighthouseAI is shaping the future of regulatory compliance at www.LighthouseAI.com.

Contact Information

Ryan Hall
Marketing Manager
ryan.hall@lighthouseai.com
(610) 298-5247

SOURCE: LighthouseAI

.

View source version on accesswire.com:
https://www.accesswire.com/803909/revolutionizing-regtech-lighthouseai-secures-strategic-investment-and-landmark-law-firm-partnership

© 2023 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.